HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 1 matching record:

Displaying record number 58813

HXB2 Location  Gag(180-188)   Gag Epitope Map
View variants at this location
Epitope TPQDLNTML   Epitope Alignment
Variants
TPtDLNTML{...h...t}   observed variant
TPsDLNTML{...h...t}   observed variant
TPQDLNTML{...a}   observed variant
TPsDLNTML{...a...v}   observed variant
{d...}aPsDLNsML{...a}   observed variant
{d...}TPsDLNsML{...v}   observed variant
{d...}TPsDLNsML{...q...v}   observed variant
TPaDLNTML{...v...v}   observed variant
TPgDLNTML{...v...v}   observed variant
TPhDLNTML{...i}   observed variant
TPtDLNTML{...i}   observed variant
TPaDLNTML{...i}   observed variant
TPsDLNTML{...i}   observed variant
TPsDLNsML   observed variant
TPsDLNsML{...t}   observed variant
TPtDLNTML{...v}   observed variant
TPQDLNTMf{...q...v...i}   observed variant
Epitope Name TL9
Species (MHC/HLA human(B*39:10, B*81:01)

Variant Details

Showing all: 17 variant(s).


Variant ID.  3155
Epitope Seq.  TPQDLNTML{...I...A}
Variant Seq.  TPtDLNTML{...h...t}
Mutations Q/T I/H A/T
Epitope Location Q3T I+35H A+60T
HXB2 Location Q182T I223H A248T
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note A mutation within TL9, Q182T had developed by 2 weeks post-infection , and putative compensatory mutations I223H and A248T had also developed by then in a B*8101-positive subject [Donor HLA = A*2601, A*8001, B*1801, B*8101, Cw*0202, Cw*0401; relatively high VL with CD4+ cell count increasing between years 3-4 post-infection]


Variant ID.  3156
Epitope Seq.  TPQDLNTML{...I...A}
Variant Seq.  TPsDLNTML{...h...t}
Mutations Q/S I/H A/T
Epitope Location Q3S I+35H A+60T
HXB2 Location Q182S I223H A248T
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note A mutation within TL9, Q182S had developed by 32 weeks post-infection , and putative compensatory mutations I223H and A248T had also developed by then in a B*8101-positive subject [Donor HLA = A*2601, A*8001, B*1801, B*8101, Cw*0202, Cw*0401; relatively high VL with CD4+ cell count increasing between years 3-4 post-infection]


Variant ID.  3157
Epitope Seq.  TPQDLNTML{...I}
Variant Seq.  TPQDLNTML{...a}
Mutations I/A
Epitope Location I+35A
HXB2 Location I223A
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note A mutation outside TL9, I223A had developed by 56 weeks post-infection in a B*8101-positive subject [Donor HLA = A*3001, A*3303, B*5301, B*8101, Cw*0401, Cw*0401; after an initial 18-24 months of control, this subject had an increased VL and decreased CD4+ T cell counts]


Variant ID.  3158
Epitope Seq.  TPQDLNTML{...I...I}
Variant Seq.  TPsDLNTML{...a...v}
Mutations Q/S I/A I/V
Epitope Location Q3S I+35A I+68V
HXB2 Location Q182S I223A I256V
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note A mutation within TL9, Q182S, had developed by 83 weeks post-infection, and putative compensatory mutations I223A and I26V had also developed by then in a B*8101-positive subject [Donor HLA = A*3001, A*3303, B*5301, B*8101, Cw*0401, Cw*0401; after an initial 18-24 months of control, this subject had an increased VL and decreased CD4+ T cell counts]


Variant ID.  3159
Epitope Seq.  {E...}TPQDLNTML{...I}
Variant Seq.  {d...}aPsDLNsML{...a}
Mutations T/A E/D Q/S I/A T/S
Epitope Location T1A E-3D Q3S I+35A T7S
HXB2 Location T180A E177D Q182S I223A T186S
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note Mutations within TL9, E177D, T180A, Q182S had developed by 108 weeks post-infection, and putative compensatory mutations I223A had also developed by then in a B*8101-positive subject [Donor HLA = A*3001, A*3303, B*5301, B*8101, Cw*0401, Cw*0401; after an initial 18-24 months of control, this subject had an increased VL and decreased CD4+ T cell counts]


Variant ID.  3160
Epitope Seq.  {E...}TPQDLNTML{...I}
Variant Seq.  {d...}TPsDLNsML{...v}
Mutations E/D Q/S I/V T/S
Epitope Location E-3D Q3S I+35V T7S
HXB2 Location E177D Q182S I223V T186S
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note Mutations within TL9, E177D, Q182S had developed by 108 weeks post-infection, and putative compensatory mutations I223V had also developed by then in a B*8101-positive subject [Donor HLA = A*3001, A*3303, B*5301, B*8101, Cw*0401, Cw*0401; after an initial 18-24 months of control, this subject had an increased VL and decreased CD4+ T cell counts]. The very same set of mutations developed in a B*3910-positive subject too, by 9 weeks post-infection [Donor HLA = A*3001, A*4301, B*3901, B*4202, Cw*1203, Cw*1701; a controller of infection]


Variant ID.  3161
Epitope Seq.  {E...}TPQDLNTML{...H...I}
Variant Seq.  {d...}TPsDLNsML{...q...v}
Mutations E/D Q/S H/Q I/V T/S
Epitope Location E-3D Q3S H+31Q I+35V T7S
HXB2 Location E177D Q182S H219Q I223V T186S
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note Mutations within TL9, E177D, Q182S had developed by 108 weeks post-infection, and putative compensatory mutations H219Q, I223V had also developed by then in a B*3910-positive subject, by 85 weeks post-infection [Donor HLA = A*3001, A*4301, B*3901, B*4202, Cw*1203, Cw*1701; a controller of infection]


Variant ID.  3162
Epitope Seq.  TPQDLNTML{...I...I}
Variant Seq.  TPaDLNTML{...v...v}
Mutations Q/A I/V I/V
Epitope Location Q3A I+35V I+68V
HXB2 Location Q182A I223V I256V
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note A mutation within TL9, Q182A had developed by 8 weeks post-infection, and putative compensatory mutations I223V and !256V had also developed by then in a B*3910-positive subject, weeks post-infection [Donor HLA = A*3001, A*4301, B*3901, B*4202, Cw*1203, Cw*1701; a controller of infection]


Variant ID.  3163
Epitope Seq.  TPQDLNTML{...I...I}
Variant Seq.  TPgDLNTML{...v...v}
Mutations Q/G I/V I/V
Epitope Location Q3G I+35V I+68V
HXB2 Location Q182G I223V I256V
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note A mutation within TL9, Q182G had developed by 28 weeks post-infection, and putative compensatory mutations I223V and I256V had also developed by then in a B*3910-positive subject [Donor HLA = A*3001, A*4301, B*3901, B*4202, Cw*1203, Cw*1701; a controller of infection]


Variant ID.  3164
Epitope Seq.  TPQDLNTML{...M}
Variant Seq.  TPhDLNTML{...i}
Mutations Q/H M/I
Epitope Location Q3H M+62I
HXB2 Location Q182H M250I
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note A mutation within TL9, Q182H, had developed by 50 weeks post-infection, and a putative compensatory mutation, M250I, had also developed by then in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor].


Variant ID.  3165
Epitope Seq.  TPQDLNTML{...M}
Variant Seq.  TPtDLNTML{...i}
Mutations Q/T M/I
Epitope Location Q3T M+62I
HXB2 Location Q182T M250I
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note A mutation within TL9, Q182T, had developed by 54 weeks post-infection, and a putative compensatory mutation, M250I, had also developed by then in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor].


Variant ID.  3166
Epitope Seq.  TPQDLNTML{...M}
Variant Seq.  TPaDLNTML{...i}
Mutations Q/A M/I
Epitope Location Q3A M+62I
HXB2 Location Q182A M250I
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note A mutation within TL9, Q182A, had developed by 71 weeks post-infection, and a putative compensatory mutation, M250I, had also developed by then in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor].


Variant ID.  3167
Epitope Seq.  TPQDLNTML{...M}
Variant Seq.  TPsDLNTML{...i}
Mutations Q/S M/I
Epitope Location Q3S M+62I
HXB2 Location Q182S M250I
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note A mutation within TL9, Q182S, had developed by 84 weeks post-infection, and a putative compensatory mutation, M250I, had also developed by then in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor].


Variant ID.  3168
Epitope Seq.  TPQDLNTML
Variant Seq.  TPsDLNsML
Mutations Q/S T/S
Epitope Location Q3S T7S
HXB2 Location Q182S T186S
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note Mutations within TL9, Q182S and T186S had developed by 97 weeks post-infection in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor].


Variant ID.  3169
Epitope Seq.  TPQDLNTML{...A}
Variant Seq.  TPsDLNsML{...t}
Mutations Q/S A/T T/S
Epitope Location Q3S A+60T T7S
HXB2 Location Q182S A248T T186S
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note Mutations within TL9, Q182S and T186S had developed by 110 weeks post-infection, as well as a putative compensatory mutation at A248T in a B*8101-positive subject [Donor HLA = A*3009, A*4301, B*5802, B*8101, Cw*0401, Cw*0401; this subject was a controller for the first 18-24 months and thereafter became a progressor].


Variant ID.  3170
Epitope Seq.  TPQDLNTML{...I}
Variant Seq.  TPtDLNTML{...v}
Mutations Q/T I/V
Epitope Location Q3T I+68V
HXB2 Location Q182T I256V
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note A mutation within TL9, Q182T, had developed by 53 weeks post-infection, and putative compensatory mutation I256V had also developed by then in a B*4201-positive subject.


Variant ID.  3171
Epitope Seq.  TPQDLNTML{...H...I...M}
Variant Seq.  TPQDLNTMf{...q...v...i}
Mutations H/Q I/V M/I L/F
Epitope Location H31Q I35V M62I L9F
HXB2 Location H219Q I223V M250I L188F
Mutation Type OV: observed variant
Epitope Subtype C
Variant Subtype C
Method Sequence
Note A mutation within TL9, L188F had developed by 76 weeks post-infection, and putative compensatory mutations H219Q, I223V and M250I had also developed by then in a B*4201, Cw*0802-positive subject

References

Ntale2012 R. S. Ntale, D. R. Chopera, N. K. Ngandu, D. Assis de Rosa, L. Zembe, H. Gamieldien, M. Mlotshwa, L. Werner, Z. Woodman, K. Mlisana, S. Abdool Karim, C. M. Gray, C. Williamson, and CAPRISA 002 Study Team. Temporal Association of HLA-B*81:01- and HLA-B*39:10-Mediated HIV-1 p24 Sequence Evolution with Disease Progression. J. Virol., 86(22):12013-12024, Nov 2012. PubMed ID: 22933291. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health